Sec Form 13G Filing - Alaska Permanent Fund Corp filing for Vir Biotechnology Inc. (VIR) - 2021-02-16

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

______________

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2 - Exit Filing)*

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

(Continued on following pages)

92764N 102
1	NAME OF REPORTING PERSONS   Alaska Permanent Fund Corporation
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) ☐ (b) ☐
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION   Alaska
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER 3,833,333
	6	SHARED VOTING POWER 59,707
	7	SOLE DISPOSITIVE POWER 3,833,333
	8	SHARED DISPOSITIVE POWER 59,707
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,893,040
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES   ☐
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.06%*
12	TYPE OF REPORTING PERSON OO

AMENDMENT NO. 2 TO SCHEDULE 13G

Reference is hereby made to the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Common Stock of the Issuer on December 5, 2019 (the “Schedule 13G”) and amendment No. 1 to the Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Common Stock of the Issuer on May 7, 2020 (the “Amendment No. 1 to Schedule 13G”). Terms defined in the Schedule 13G and Amendment No. 1 to Schedule 13G are used herein as so defined.

The following Items of the Schedule 13G are amended and restated to read in their entirety as follows:

Item 4.	Ownership.
	(a)	Amount beneficially owned:
		(i)	The Reporting Person directly owns 3,833,333 shares of the Issuer’s common stock.
		(ii)	Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P. directly own 59,707 shares of the Issuer’s common stock. The Reporting Person is a limited partner in each of Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P. and may be deemed to beneficially own the shares held by such funds.
	(b)	Percent of class:
		See Row 11 of the cover page for the Reporting Person.
	(c)	Number of shares as to which the Reporting Person has:
		(i)	Sole power to vote or to direct the vote
			See Row 5 of the cover page for the Reporting Person.
		(ii)	Shares power to vote or to direct the vote:
			See Row 6 of the cover page for the Reporting Person.
		(iii)	Sole power to dispose or to direct the disposition of:
			See Row 7 of the cover page for the Reporting Person.
		(iv)	Shared power to dispose or to direct the disposition of:
			See Row 8 of the cover page for the Reporting Person.
Item 5.	Ownership of Five Percent of Less of a Class
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: ☒

	As show from the percentage of class calculated herein, the Reporting Person has ceased to be a beneficial owner of more than five percent of the Issuer’s common stock. The filing of this Amendment No. 2 to the Schedule 13G constitutes an exit filing.
Item 10.	Certifications.
	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:  February 15, 2021

*The Reporting Person disclaims beneficial ownership over the securities reported herein as being owned by Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P., except to the extent of the Reporting Persons’ pecuniary interest therein.

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partn er of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).